Biotech | December 14, 2021
Samsung Biologics expands tie-up with AstraZeneca to include cancer therapy
The company will manufacture a cancer immunotherapy product from 2022
The company will manufacture a cancer immunotherapy product from 2022
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
FDA changes inspection classification of the facility to Voluntary Action Indicated
Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
The company will provide recyclability services to brands with a final goal to help them move to fully recyclable packaging
The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
The company will donate 5000 nebulizers to primary health care centres in rural India
Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA)
The platform’s technology works as a compression algorithm for molecular testing
Subscribe To Our Newsletter & Stay Updated
